June 2022
Price: £95 PLUS VAT
Format: DOWNLOADABLE PDF
This conference discussed highly specialised medicine and treatment in the UK, including key issues for development, research, and regulation.
Taking place following the recent update to the highly specialised technologies evaluation at NICE, it was an opportunity to discuss the future landscape, navigating changes in approach, and addressing challenges in orphan drug development.
We are pleased to have been able to include keynote sessions with: Brad Groves, Associate Director, Managed Access, NICE; and Sheela Upadhyaya, Rare Diseases and Rapid-C19 Strategic Advisor, Centre for Health Technology Evaluation, NICE - as well as contributions from Dr Richard Scott, Chief Medical Officer, Genomics England; and Dr Marc Bailey, Chief Science and Innovation Officer, Medicines and Healthcare products Regulatory Agency (MHRA).
Delegates discussed the impact of changes to evaluation in improving patient access and engagement in the context of the Rare Diseases Action Plan.
They also considered priorities for investment, collaboration and achieving value for money - as well as the thinking on effective managed access programmes, following the consultation held on the new Innovative Medicines Fund.
Sessions in the agenda included:
- highly specialised technology evaluation - the future outlook
- new approaches to evaluation - opportunities, challenges and implementation
- the Innovative Medicines Fund and new NICE methods and processes
- orphan drug development - new approaches
- managed access programme effectiveness
- value for money in healthcare assessments
- patient access to innovation - the Innovative Medicines Fund: scope, priorities and looking forward
- genomics - taking forward opportunities
- innovation - support and developing new approaches to regulation and data use
- research and development - priorities, investment, opportunities for collaboration, and latest thinking on delivering innovative interventions earlier in the course of disease
Further keynote speakers included: Dr Paul Catchpole, Director, Value and Access Policy, ABPI; Martina Garau, Director, Office of Health Economics; Dr Mark MacGregor, Chairman, Scottish Medicines Consortium; Toni Mathieson, Chief Executive, Niemann-Pick UK and Chair, LSD Collaborative; and Sean Richardson, Vice President and General Manager, UK and Ireland, Alexion, AstraZeneca Rare Disease.
The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from DHSC; MHRA; OLS; the Department of Health, Ireland; HM Treasury; DIT; DWP; GLD; The Scottish Government and the Welsh Government.
